152 related articles for article (PubMed ID: 19631530)
21. Design, synthesis, and
Corrigan TS; Lotti Diaz LM; Border SE; Ratigan SC; Kasper KQ; Sojka D; Fajtova P; Caffrey CR; Salvesen GS; McElroy CA; Hadad CM; Doğan Ekici Ö
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1387-1402. PubMed ID: 32633155
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.
Takeda S; Chen DY; Westergard TD; Fisher JK; Rubens JA; Sasagawa S; Kan JT; Korsmeyer SJ; Cheng EH; Hsieh JJ
Genes Dev; 2006 Sep; 20(17):2397-409. PubMed ID: 16951254
[TBL] [Abstract][Full Text] [Related]
23. N-Terminal peptidic boronic acids selectively inhibit human ClpXP.
Knott K; Fishovitz J; Thorpe SB; Lee I; Santos WL
Org Biomol Chem; 2010 Aug; 8(15):3451-6. PubMed ID: 20523950
[TBL] [Abstract][Full Text] [Related]
24. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.
Ettari R; Nizi E; Di Francesco ME; Dude MA; Pradel G; Vicík R; Schirmeister T; Micale N; Grasso S; Zappalà M
J Med Chem; 2008 Feb; 51(4):988-96. PubMed ID: 18232656
[TBL] [Abstract][Full Text] [Related]
25. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.
Zhao Z; Wang L; Volk AG; Birch NW; Stoltz KL; Bartom ET; Marshall SA; Rendleman EJ; Nestler CM; Shilati J; Schiltz GE; Crispino JD; Shilatifard A
Genes Dev; 2019 Jan; 33(1-2):61-74. PubMed ID: 30573454
[TBL] [Abstract][Full Text] [Related]
26. Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.
Sabiani S; Geppert T; Engelbrecht C; Kowarz E; Schneider G; Marschalek R
EBioMedicine; 2015 May; 2(5):386-95. PubMed ID: 26137584
[TBL] [Abstract][Full Text] [Related]
27. Taspase1 processing alters TFIIA cofactor properties in the regulation of TFIID.
Malecová B; Caputo VS; Lee DF; Hsieh JJ; Oelgeschläger T
Transcription; 2015; 6(2):21-32. PubMed ID: 25996597
[TBL] [Abstract][Full Text] [Related]
28. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
29. Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.
Ettari R; Bonaccorso C; Micale N; Heindl C; Schirmeister T; Calabrò ML; Grasso S; Zappalà M
ChemMedChem; 2011 Jul; 6(7):1228-37. PubMed ID: 21506279
[TBL] [Abstract][Full Text] [Related]
30. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
[TBL] [Abstract][Full Text] [Related]
31. Difluoroketones as inhibitors of matrix metalloprotease-13.
Reiter LA; Martinelli GJ; Reeves LA; Mitchell PG
Bioorg Med Chem Lett; 2000 Jul; 10(14):1581-4. PubMed ID: 10915056
[TBL] [Abstract][Full Text] [Related]
32. Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.
Chen DY; Liu H; Takeda S; Tu HC; Sasagawa S; Van Tine BA; Lu D; Cheng EH; Hsieh JJ
Cancer Res; 2010 Jul; 70(13):5358-67. PubMed ID: 20516119
[TBL] [Abstract][Full Text] [Related]
33. Peptidyl fluoro-ketones as proteolytic enzyme inhibitors.
Sani M; Sinisi R; Viani F
Curr Top Med Chem; 2006; 6(14):1545-66. PubMed ID: 16918467
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
[TBL] [Abstract][Full Text] [Related]
35. 2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of gamma-secretase.
Prasad CV; Vig S; Smith DW; Gao Q; Polson CT; Corsa JA; Guss VL; Loo A; Barten DM; Zheng M; Felsenstein KM; Roberts SB
Bioorg Med Chem Lett; 2004 Jul; 14(13):3535-8. PubMed ID: 15177468
[TBL] [Abstract][Full Text] [Related]
36. Structural insights into the function of the catalytically active human Taspase1.
Nagaratnam N; Delker SL; Jernigan R; Edwards TE; Snider J; Thifault D; Williams D; Nannenga BL; Stofega M; Sambucetti L; Hsieh JJ; Flint AJ; Fromme P; Martin-Garcia JM
Structure; 2021 Aug; 29(8):873-885.e5. PubMed ID: 33784495
[TBL] [Abstract][Full Text] [Related]
37. Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo.
Bier C; Knauer SK; Wünsch D; Kunst L; Scheiding S; Kaiser M; Ottmann C; Krämer OH; Stauber RH
FASEB J; 2012 Aug; 26(8):3421-9. PubMed ID: 22623586
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.
Adams J; Behnke M; Chen S; Cruickshank AA; Dick LR; Grenier L; Klunder JM; Ma YT; Plamondon L; Stein RL
Bioorg Med Chem Lett; 1998 Feb; 8(4):333-8. PubMed ID: 9871680
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.
Bier C; Hecht R; Kunst L; Scheiding S; Wünsch D; Goesswein D; Schneider G; Krämer OH; Knauer SK; Stauber RH
PLoS One; 2012; 7(5):e34142. PubMed ID: 22570686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
